Floatz logo

Chimeric Antigen Receptor Modified T Cells Infusion

Multiple Myeloma

Centre Hospitalier Universitaire de Saint EtienneCell therapyPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
59/ 100

Competitive context

343 Active assets in the Multiple Myeloma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
GlaxoSmithKline
Phase 4BB
Thalidomide
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
Inno-206
GlaxoSmithKline
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Janssen Research & Development, LLC
Phase 4BB
cc-5013
Universitätsklinikum Hamburg-Eppendorf
Phase 4BB

View all 50 →

Same molecule, other indications

Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:

B Cell LymphomaDormant
BB
Indicative ·
71 / 100
View asset →
Non Hodgkin LymphomaDormant
BB
Indicative ·
67 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →